botulinum toxin

Bio & Pharma Daewoong wins permission for Nabota in Argentina

South Korea's Daewoong Pharmaceutical Co. announced on Monday that its botulinum toxin Nabota received product approval from Argentina's National Ad...

Bio & Pharma Medytox to supply $73 mn botulinum toxin to Brazilian firm

South Korea's biopharmaceutical firm Medytox Inc. announced on Tuesday that it signed a contract with Brazilian pharmaceutical company Blau Farmaceu...

Bio & Pharma Medytox to enter China’s botulinum toxin market with Newlux

South Korean pharmaceutical company Medytox Inc. on Tuesday announced its plan to enter the Chinese market for botulinum toxins (BTX) with its cut...

Bio & Pharma Hugel resubmits application to FDA for botulinum toxin product

South Korea's biopharmaceutical company Hugel Inc., announced on Friday that it has resubmitted applications to the US Food and Drug Administration ...

Bio & Pharma Daewoong's Nabota exceeds 600,000 customers in US

South Korea's Daewoong Pharmaceutical said on Thursday that its local loyalty program for Nabota (American name: Jeuveau) in the US, a botulinum tox...

Bio & Pharma Daewoong Pharma to build third botulinum toxin plant for $746 mn

South Korea’s Daewoong Pharmaceutical next year will open a third plant to greatly expand annual output of its botulinum toxin Nabota at a cos...

Beauty & Cosmetics Botulinum toxin resistance emerges as key factor for safe use

As demand for botulinum toxin for aesthetic purposes is globally increasing, safe use of the drug has emerged as one of the most important issues in...

Bio & Pharma Daewoong’s Nabota expands into Germany, Austria

South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday it had launched its botulinum toxin product Nabota in Germany and Austria through i...

Bio & Pharma Dubai delegation conducts due diligence on Medytox's plant in Korea

South Korea's biopharmaceutical firm Medytox Inc. said on Monday that a high-level delegation led by Dubai Science Park (DSP) under Dubai's state-ow...

Bio & Pharma Jetema applies to test its botulinum toxin in US from July

South Korea's bio-esthetic pharmaceutical company Jetema Co. will hold clinical trials in the US to advance to the American market, the world's bigg...

Bio & Pharma US calls on 2 S.Korean pharmaceutical companies for swift end to legal battle

Following its lawsuit against Daewoong Pharmaceutical, South Korea's Medytox Inc. is waging an all-out legal war against domestic counterpart Hugel ...

Bio & Pharma Daewoong Pharma's botulinum toxin Nabota proves long-lasting effect

Daewoong Pharmaceutical said on Friday that a high-dose administration of botulinum toxin Nabota (US brand name: Jeuveau) to patients with frown wri...

Bio & Pharma Daewoong Pharma's botulinum toxin Nabota wins approval from Australia

Daewoong Pharmaceutical said on Wednesday that its botulinum toxin formulation Nabota (overseas brand name: Nuceiva) won approval in Australia on Ja...

Bio & Pharma Medytox to build plant for finished toxin products in Dubai

South Korea's biopharmaceutical company Medytox Inc. will build a plant for finished products containing botulinum toxin in the United Arab Emirates...